revumenib
syndax pharma
['bet', 'revumenib', 'venetoclax', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'augment,data', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'augment-101', 'leukemia', 'myeloid']
revumenib in npm1m/kmt2ar r/r leukemias: 30% cr, 50%crh is looking very encouraging. we ought to find synergistic combinations to make it better. #ash22 
Heme-Onc Fellow @UChicago | Alumni of @OhioStateIMRes, @CCLRI | #Leukemia, #MDS, #CHIP physician-scientist. Tweets=own opinions.